ALS drug

FDA Gives Accelerated Approval to Biogen’s ALS Drug

Imagine you’re a plant trying to grow, but you need extra sunlight to thrive. Well, that’s how Biogen’s drug for treating amyotrophic lateral sclerosis (ALS) feels under the U.S. Food and Drug Administration’s accelerated approval pathway! The FDA has given the green light to Qalsody, a drug specifically designed to treat an inherited form of […]

Published on April 25, 2023

FDA Panel Backs Accelerated Approval for ALS Drug

In a momentous move, a group of experts from the FDA have given their seal of approval to expedite the approval process for Biogen Inc’s potential breakthrough treatment for ALS, a devastating neurological disease famously associated with baseball legend Lou Gehrig. The thrilling decision comes after an intensive review of compelling evidence that suggests the […]

Published on March 23, 2023

FDA Approves Amylyx Drug to Slow ALS Progression

In a remarkable development, the U.S. Food and Drug Administration has granted approval to Amylyx Pharmaceuticals Inc’s groundbreaking drug that can effectively slow down the progression of ALS, also known as amyotrophic lateral sclerosis. This monumental breakthrough may not only extend the lifespan of individuals with ALS, but it could also potentially postpone the occurrence […]

Published on September 29, 2022